Open AccessRandomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
Author(s) -
William D. Chey,
Gregory S. Sayuk,
Wilmin Bartolini,
David S. Reasner,
Susan M. Fox,
Wieslaw Bochenek,
Ramesh Boinpally,
Elizabeth P. Shea,
Kenneth Tripp,
Niels Borgstein
Publication year - 2020
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/ajg.0000000000000967
Subject(s) - medicine , irritable bowel syndrome , placebo , constipation , gastroenterology , abdominal pain , lubiprostone , defecation , adverse effect , chronic constipation , pathology , alternative medicine
Immediate-release (IR) formulation of linaclotide 290 μg improves abdominal pain and constipation (APC) in patients with irritable bowel syndrome (IBS) with constipation. Delayed-release (DR) formulations were developed on the premise that targeting the ileum (delayed-release formulation 1 [DR1]) or ileocecal junction and cecum (MD-7246, formerly DR2) would modulate linaclotide's secretory effects while preserving pain relief effects.